Advertisement

Organisation › Details
Symetis AG
Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions. Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use. Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016. Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil. *
![]() |
Start | 2001-01-01 splitoff |
Group | Boston Scientific (Group) | |
Predecessor | University of Zurich (UZH) | |
![]() |
Industry | tissue engineering / regenerative medicine |
Industry 2 | medical device | |
![]() |
Person | Essinger, Jacques R. (Symetis 201703 CEO) |
![]() |
Region | Ecublens VD |
Country | Switzerland | |
Street | 11 Chemin de la Venoge | |
City | 1024 Ecublens VD | |
Tel | +41-21-651-0160 | |
Address record changed: 2018-07-24 | ||
Basic data | Employees | D: 101 to 500 (2017-03-30) |
Currency | CHF | |
Annual sales | 38,400,000 (revenues (2016) 2016-12-31) | |
* Document for �About Section�: Symetis AG. (3/30/17). "Press Release: Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement". Ecublens. | ||
Record changed: 2018-10-31 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Boston Scientific (Group)
- [1] Symetis AG. (3/30/17). "Press Release: Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement". Ecublens....
- [2] Boston Scientific Corporation. (3/30/17). "Press Release: Boston Scientific Announces Agreement to Acquire Symetis". Marlborough, MA....
- [3] Symetis AG. (3/20/17). "Press Release: Symetis Launches Its IPO on Euronext Paris [This document may not be released, published or distributed, directly or indirectly, in or into Australia, Canada, Japan or the United States]"....
- [4] Bayer AG. (9/2/14). "Press Release: Bayer Closes on Divestiture of Interventional Device Business to Boston Scientific". Leverkusen....
- [5] Bayer AG. (5/15/14). "Press Release: Bayer to Divest Interventional Device Business to Boston Scientific for $415 Million". Leverkusen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top